Navigation Links
ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent
Date:10/22/2007

WASHINGTON, DC OCTOBER 22, 2007 Late-breaking results from the ENDEAVOR IV trial, presented at TCT 2007, the annual scientific symposium of the Cardiovascular Research Foundation, show that the Endeavor zotarolimus-eluting stent met the trials primary endpoint, demonstrating a similar overall safety profile (equivalent rates of death, heart attack, and repeat procedures) to the Taxus paclitaxel-eluting stent at 1 year.

In addition, the Endeavor stent showed a lower rate of less-severe (non-Q-wave) heart attacks at 30 days, but a higher rate of angiographic late loss (artery re-narrowing) at eight months compared to the Taxus stent.

The primary endpoint of the trial, non-inferiority as measured by target vessel failure (TVF) between the two stents, was met, said Martin B. Leon, MD, Founder and Chairman Emeritus, CRF and Professor of Medicine at Columbia University Medical Center. TVF occurred in 6.6 percent of patients receiving the Endeavor stent and 7.2 percent of patients receiving the Taxus stent, a difference that was not statistically significant. The Endeavor stent also demonstrated equivalence to Taxus in several long term measures.

At 12 months, the difference between the rates of target lesion revascularization with the Endeavor (4.5 percent) and Taxus (3.2 percent) stents was not statistically significant. Likewise, target vessel revascularization rates at 12 months were also similar (6.3 percent with Endeavor vs. 6.7 percent with Taxus).

Interestingly, at 30 days, rates of less-severe heart attacks were 0.5 percent with Endeavor compared with 2.2 percent with Taxus, a statistically significant difference. Late loss at eight months, meanwhile, was significantly greater with Endeavor (0.67 mm) compared with Taxus (0.42 mm).

Importantly, in the diabetic subset of 477 patients, Endeavor had similar efficacy compared with Taxus including target lesion revascularization and in-segment restenosis.

The Endeavor IV trial included 1,548 patients at 80 locations and was randomized to treatment with either the Endeavor or Taxus stent.


'/>"/>

Contact: David Harrison
david@harrisoncommunications.net
410-804-1728
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. ENDEAVOR III Trial Reports Key Findings on New-generation Stent
2. Human Genome Project Achieves Technological Triumph
3. A Village in Madhya Pradesh Achieves Total Sanitation
4. PRIMARY PULMONARY HYPERTENSION GENE DISCOVERED
5. Is caries in primary and permanent tooth related?
6. Evidence against use of Beta blockers as first choice in the treatment of primary hypertension
7. Shortage Of Funds In Primary Care Trust In UK
8. What Will Primary Care Look Like In England by 2015?
9. Primary Health Care MoU Signed on the Sidelines of the PBD
10. Primary Care centers to provide out patient treatment
11. Early Detection Of Primary Liver Cancer Would Save Millions Of Lives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... ... From a health perspective, 2017 will clearly be the Year of the Gut. ... health and general physical well-being. The New York Times suggested a “ Gut Makeover ... Charlottesville restaurant, good gut health is clearly on the menu. Threepenny Cafe ...
(Date:1/18/2017)... , ... January 18, 2017 , ... The V Foundation ... Team V, its official endurance training and fundraising team, to compete in the Boston ... welcomes those inspired to finish the world’s oldest annual marathon to join Team V ...
(Date:1/18/2017)... ... 2017 , ... At Hallmark Nameplate, their commitment to quality is what sets ... ISO 13485. This certification is another way they are making constant strides to provide ... they need. , The ISO 13485 Certification is a major accomplishment for Hallmark Nameplate ...
(Date:1/18/2017)... ... January 18, 2017 , ... Rollerblade®, the worldwide ... (ABT), an innovative braking system that allows skaters of all levels to stop ... the biggest concerns of beginner and intermediate skaters – learning how to brake ...
(Date:1/17/2017)... ... , ... Gym Source, America’s leading retailer of premium residential and commercial fitness ... Miami, FL. , “We are elated to be opening this new showroom,” explains Tom ... to give clients a seamless and motivating shopping experience.” , Every fitness journey is ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... Research and Markets has announced the addition of the ... to their offering. ... The global CINV drugs market to grow at a CAGR ... Surgery Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. To calculate ...
(Date:1/18/2017)... 17, 2017  With an annual growth ranging from 6% to 10%, ... (Jakarta International Expo, March 22-24, 2017) serves the industry by fostering the regional ... SEA 2017? Investment Forum ASEAN -- ... Richer conference content Enhanced business matchmaking program ... ...
(Date:1/18/2017)... ANTONIO , Jan. 18, 2017   Seno ... process of diagnosing breast cancer through the development of ... of Steve Miller as SVP of Engineering. ... Product Realization at FUJIFILM SonoSite, with headquarters in ... the majority of his 30-year career to the development ...
Breaking Medicine Technology: